Literature DB >> 8845618

Cervical Castleman's disease associated with benign M-proteinemia: report of a case.

M Komatsu1, T Ehara, T Kuroda.   

Abstract

We report the unusual case of a 77-year-old man with cervical Castleman's disease associated with benign M-proteinemia. The patient was found to have an anterior cervical tumor during a follow-up examination after surgery for early gastric cancer, at which time blood biochemistry tests revealed M-proteinemia at the position of beta-globulin with a high level of IgG and low levels of IgA and IgM. Serum protein immunoelectrophoresis revealed M-protein consisting of the IgG-k chain, and urine protein immuno-electrophoresis demonstrated Bence Jones protein consisting of the chain. No abnormalities were noted in bone marrow aspiration or bone scintigram. The results of imaging and fine-needle aspiration biopsy of the tumor led to a pre-operative diagnosis of cervical malignant lymphoma with suspected M-proteinemia derived from this disease, and resection of the anterior cervical tumor with bilateral neck dissection was performed. Histopathological examination subsequently demonstrated four mixed-type tumors of Castleman's disease. The pathogenesis of Castleman's disease remains unknown; however, we speculate that the complication of benign M-proteinemia in this patient was not incidental, but caused by an underlying immunological abnormality of the B cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8845618     DOI: 10.1007/bf00311511

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  9 in total

1.  Localized mediastinal lymphnode hyperplasia resembling thymoma.

Authors:  B CASTLEMAN; L IVERSON; V P MENENDEZ
Journal:  Cancer       Date:  1956 Jul-Aug       Impact factor: 6.860

2.  Castleman's disease in POEMS syndrome with elevated interleukin-6.

Authors:  R N Mandler; D P Kerrigan; J Smart; W Kuis; P Villiger; M Lotz
Journal:  Cancer       Date:  1992-06-01       Impact factor: 6.860

3.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.

Authors:  K Yoshizaki; T Matsuda; N Nishimoto; T Kuritani; L Taeho; K Aozasa; T Nakahata; H Kawai; H Tagoh; T Komori
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

4.  Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations.

Authors:  A R Keller; L Hochholzer; B Castleman
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

5.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

Authors:  J T Beck; S M Hsu; J Wijdenes; R Bataille; B Klein; D Vesole; K Hayden; S Jagannath; B Barlogie
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

6.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Authors:  G Frizzera; B A Peterson; E D Bayrd; A Goldman
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

7.  The Crow-Fukase syndrome: a study of 102 cases in Japan.

Authors:  T Nakanishi; I Sobue; Y Toyokura; H Nishitani; Y Kuroiwa; E Satoyoshi; T Tsubaki; A Igata; Y Ozaki
Journal:  Neurology       Date:  1984-06       Impact factor: 9.910

8.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

Authors:  M Kawano; T Hirano; T Matsuda; T Taga; Y Horii; K Iwato; H Asaoku; B Tang; O Tanabe; H Tanaka
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

9.  Multicentric giant lymph node hyperplasia.

Authors:  A R Gaba; R S Stein; D L Sweet; D Variakojis
Journal:  Am J Clin Pathol       Date:  1978-01       Impact factor: 2.493

  9 in total
  1 in total

1.  Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.

Authors:  Zhen-gang Yuan; Xiao-yi Dun; Yong-hua Li; Jian Hou
Journal:  J Hematol Oncol       Date:  2009-04-28       Impact factor: 17.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.